https://www.fiercebiotech.com/r-d/updated-eli-lilly-offers-evidence-of-twice-failed-solanezumab-s-impact-on-alzheimer-s
UPDATED: Eli Lilly offers evidence of twice-failed solanezumab's impact on Alzheimer's | Fierce...
Jul 22, 2015 - Eli Lilly says that it has evidence to show that its amyloid-busting drug solanezumab has a distinct impact on Alzheimer's disease, pointing to a delayed-start...
https://pubmed.ncbi.nlm.nih.gov/29365294/
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by...
due totrialmild
https://www.semanticscholar.org/topic/solanezumab/326499
solanezumab | Semantic Scholar
A humanized monoclonal antibody (IgG1) raised against amyloid beta peptides with Alzheimer disease treatment application. Solanezumab recognizes and binds the...
semanticscholar